Global Anticoagulation Therapy Market, By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, and Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, and Others), Drug Type (Bivalirudin, Dabigatran, Edoxaban, Betrixaban, Rivaroxaban, Apixaban, Enoxaparin, Dalteparin, and Others), Route of Administration (Oral and Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, and Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, and Heart Valve Replacement), Type (Generics and Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Industry Trends and Forecast to 2031.
Anticoagulation Therapy Market Analysis and Size
The anticoagulation therapy market is experiencing significant advancements, driven by the latest methods and technologies. This growth is fueled by increased use and demand for more effective treatments, such as novel oral anticoagulants (NOACs) and precision medicine approaches. These innovations aim to enhance patient outcomes by offering safer and more tailored therapeutic options, marking a transformative phase in managing thrombotic disorders.
The global anticoagulation therapy market size was valued at USD 29.97 billion in 2023 and is projected to reach USD 57.10 billion by 2031, with a CAGR of 8.39% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, and Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, and Others), Drug Type (Bivalirudin, Dabigatran, Edoxaban, Betrixaban, Rivaroxaban, Apixaban, Enoxaparin, Dalteparin, and Others), Route of Administration (Oral and Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, and Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, and Heart Valve Replacement), Type (Generics and Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Hikma Pharmaceuticals PLC (Jordan), Mylan N.V. (Netherlands), Teva Pharmaceutical Industries Ltd. (Israel, Novartis AG (Switzerland), Eisai Co., Ltd. (Japan), Pfizer Inc. (U.S.), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Fresenius Kabi AG (Germany), Aspen Holdings (South Africa), Shanghai Fosun Pharmaceutical(Group)Co., Ltd. (China), Cipla Inc. (India), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Eagle Pharmaceuticals, Inc. (U.S.), Endo International plc (Ireland), Mitsubishi Tanabe Pharma Corporation (Japan), Portola Pharmaceuticals, Inc. (U.S.), and Taro Pharmaceutical Industries Ltd. (Israel)
|
|
Market Opportunities
|
|
Market Definition
Anticoagulation therapy involves the use of medications to prevent blood clot formation in patients at risk of thrombosis. These drugs, such as warfarin or heparin, work by interfering with the blood's ability to clot, reducing the likelihood of dangerous clotting within blood vessels. This therapy is crucial in managing conditions such as deep vein thrombosis, pulmonary embolism, and preventing stroke in individuals with atrial fibrillation.
Anticoagulation Therapy Market Dynamics
Drivers
- Increasing Prevalence of Cardiovascular Diseases
The rising global prevalence of cardiovascular diseases, including heart attacks and strokes, has fueled the demand for anticoagulation therapy. These conditions often require preventive measures against blood clotting to manage and reduce risks. For instance, atrial fibrillation, a common heart rhythm disorder, significantly increases the risk of stroke and necessitates ongoing anticoagulant treatment to prevent clot formation and potential stroke events, thereby driving growth in the anticoagulation therapy market.
- Growing Aging Population
The growing aging population is a pivotal driver for the anticoagulation therapy market. As people age, conditions such as atrial fibrillation and deep vein thrombosis become more prevalent. For instance, individuals over 65 are at higher risk of developing atrial fibrillation, necessitating anticoagulation therapy to prevent strokes. This demographic shift increases the demand for anticoagulants, contributing significantly to the expansion of the market for these therapies.
Opportunities
- Advancements in Anticoagulant Drugs
Advancements in anticoagulant drugs are driving the market by continually introducing more effective treatments. For instance, the development of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) such as dabigatran, rivaroxaban, and apixaban offers patients alternatives to traditional therapies such as warfarin. These medications provide more predictable anticoagulation effects, require less frequent monitoring, and have lower risks of drug interactions, thereby improving patient outcomes and expanding the overall anticoagulation therapy market.
- Increasing Surgical Procedures
Increasing surgical procedures, particularly joint replacements and major orthopedic surgeries, drive the anticoagulation therapy market. These procedures often require prophylactic anticoagulation to prevent complications such as deep vein thrombosis (DVT) and pulmonary embolism (PE). For instance, after hip replacement surgery, patients are at high risk of DVT, necessitating the use of anticoagulants such as heparin or newer agents such as direct oral anticoagulants (DOACs). This demand fuels growth in the market for anticoagulation therapies.
Restraints/Challenges
- Side Effects and Bleeding Risks
Anticoagulants pose significant risks of bleeding, especially in elderly patients or those with specific medical conditions, which hinders their market acceptance. The potential for severe bleeding events remains a critical concern, deterring broader adoption despite their therapeutic benefits in preventing thrombotic events.
- High Cost of Therapy
The high cost of newer anticoagulants poses a significant barrier to market accessibility, particularly for patients lacking comprehensive insurance coverage or residing in lower-income regions. This financial constraint limits widespread adoption and availability, exacerbating disparities in access to essential anticoagulation therapies across global healthcare systems.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In July 2023, The Assure PT Care PT/INR Monitoring System, a collaboration between ARKRAY USA, Inc. and CoaguSense, Inc., will be available in long-term care institutions. This point-of-care test utilizes a proprietary micromechanical device for blood clotting time detection, comparable to WHO's tilt-tube method. Its wireless, portable design aims to enhance PT/INR testing productivity with instant results for timely patient care decisions
- In May 2023, Pfizer reported successful phase 3 results for marstacimab in treating hemophilia A and B, demonstrating efficacy without clotting issues. Annualized bleeding rates were significantly lower compared to current intravenous regimens, indicating clinical relevance. If approved, marstacimab would offer a flat dosage and be the first weekly subcutaneous treatment for hemophilia B
- In February 2022, Bayer's oral Factor Xia inhibitor Asundexian received fast-track designation from the FDA. In phase 2 trials, it promises safety advantages over existing anticoagulants. This potential therapy addresses a critical need for improved anticoagulation options
- In February 2022, Techdow USA Inc. launched its Heparin Sodium Injection, USP in the U.S. market. As a vertically integrated generic injectables company, this product aims to meet demand for high-quality injectable heparin sodium, contributing to healthcare accessibility and patient care in the United States
Anticoagulation Therapy Market Scope
The market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thromboembolism (AT)
- Stroke
- Others
Therapeutic Class
- Novel Oral Anticoagulants (NOAC)
- Heparin
- Vitamin K Antagonists
- Others
Drug Type
- Bivalirudin
- Dabigatran
- Edoxaban
- Betrixaban
- Rivaroxaban
- Apixaban
- Enoxaparin
- Dalteparin
- Others
Route of Administration
- Oral
- Parenteral
Therapeutic Area
- Cardiovascular
- Respiratory
- Oncology
- Nephrology
- CNS
- Others
Procedure
- Pre-Surgical Procedures
- Post-Surgical Procedures
- Kidney Dialysis
- Heart Valve Replacement
Type
- Generics
- Branded
End User
- Hospitals
- Clinics
- Homecare
- Ambulatory Surgical Centres
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Anticoagulation Therapy Market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by country, treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to expand at a significant growth rate due to the enduring administration, triple therapy anticoagulation, and increasing demand for anticoagulation drugs. The region's focus on long-term medical therapies drives the market for these treatments, reflecting sustained growth over the forecast period.
North America is expected to dominate the anticoagulation therapy market due to the proliferation of hospital-associated clinics and substantial healthcare expenditure in the region. These factors underscore its leading position in advancing anticoagulation treatments and patient care.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Anticoagulation Therapy Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Some of the major players operating in the market are:
- Hikma Pharmaceuticals PLC (Jordan)
- Mylan N.V. (Netherlands)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Novartis AG (Switzerland)
- Eisai Co., Ltd. (Japan)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- Aspen Holdings (South Africa)
- Shanghai Fosun Pharmaceutical(Group)Co., Ltd. (China)
- Cipla Inc. (India)
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH (Germany)
- Bristol-Myers Squibb Company (U.S.)
- DAIICHI SANKYO COMPANY, LIMITED (Japan)
- Eagle Pharmaceuticals, Inc. (U.S.)
- Endo International plc (Ireland)
- Mitsubishi Tanabe Pharma Corporation (Japan)
- Portola Pharmaceuticals, Inc. (U.S.)
- Taro Pharmaceutical Industries Ltd. (Israel)
SKU-